Sangamo终究没能留住陪伴公司最久的合作方。近日(2024年12月30日),Sangamo Therapeutics宣布,辉瑞终止了其在A型血友病基因疗法giroctocogene fitelparvovec的合作,不再推进上市申请以及商业化,终止协议于2025年4月21日生效。辉瑞是陪伴公司最重要的合作方,特别是Sangamo在过去两年时间内经历了曾经的合作方陆续离开之后。giro-vec...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.